ZyVersa Therapeutics Inc Stock Price, News & Analysis

ZyVersa Therapeutics (Nasdaq: ZVSA) has announced published data supporting the rationale for inhibiting inflammasome ASC with IC 100 to control chronic inflammation. The research, published in EMBO Molecular Medicine, demonstrates that extracellular ASC specks play a important role in the pathogenesis of amyloid A (AA) amyloidosis, a condition characterized by deposition of insoluble amyloid fibrils in tissues and organs.

Key findings include:

• ASC colocalization with SAA in human AA amyloidosis
• ASC specks accelerating SAA fibril formation
• Decreased splenic amyloid load in ASC-lacking mouse models
• Reduced amyloid loads in mice treated with anti-ASCPYD antibodies

ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which inhibits intra- and extracellular ASC and specks associated with multiple types of inflammasomes, potentially attenuating damaging inflammation in various inflammatory diseases.

ZyVersa Therapeutics (Nasdaq: ZVSA) announces published data showing promise for plasma levels of inflammasome ASC as a biomarker of early cognitive changes in older adults. The study, published in the International Journal of Molecular Sciences, found:

1. Elevated ASC levels in cognitively normal adults who showed decline after one year.
2. Higher ASC levels in those 70+ years old.
3. Excellent ability to differentiate between cognitive decline and normal cognition in 70+ group (AUC 0.81).

This research supports ZyVersa's development of Inflammasome ASC Inhibitor IC 100 for treating neurological and inflammatory diseases. The company aims to address the growing global dementia crisis, expected to affect 114 million people by 2040.

ZyVersa Therapeutics (ZVSA) has chosen obesity and related metabolic complications as the lead indication for its Inflammasome ASC Inhibitor IC 100. This decision is based on the growing global obesity drug market, which reached $24 billion in 2023 and is forecasted to reach up to $131 billion by 2028. Obesity affects over 40% of Americans and is associated with multiple chronic conditions, costing over $1.4 trillion annually in the US.

ZyVersa believes that IC 100, which inhibits multiple types of inflammasomes, could complement GLP-1 agonists by addressing chronic tissue inflammation not targeted by current treatments. The company plans to submit an Investigational New Drug (IND) application in Q4-2024, with Phase 1 clinical trials to follow. Preclinical collaborations are underway to assess IC 100's potential in treating atherosclerosis and obesity-related metabolic syndrome.

ZyVersa Therapeutics (ZVSA) announces publication of research demonstrating that its Inflammasome ASC Inhibitor IC 100 restored retinal structure and function in a Retinopathy of Prematurity (ROP) animal model. The study, published in Angiogenesis, showed that IC 100 suppressed retinal microglia activation, attenuated inflammation, abnormal vascularization, and retinal thinning. Key findings include:

• IC 100 decreased expression of inflammasome-related molecules and inflammatory cytokines
• It reduced ASC speck formation and microglial activation
• Structural and functional improvements correlated with corrections of hyperoxia-modulated gene pathways

This research supports IC 100's potential in treating ROP, a leading cause of childhood blindness worldwide, and adds to its promising indications including early Alzheimer's disease, multiple sclerosis, and acute respiratory distress syndrome.

ZyVersa Therapeutics (Nasdaq: ZVSA) announced that its CEO, Stephen C. Glover, will speak at the H.C. Wainwright 3rd Annual Kidney Conference on July 15, 2024. During his presentation, Glover will discuss the unique mechanism of Cholesterol Efflux Mediator™ VAR 200, which is in Phase 2a development for treating kidney diseases. The conference, held virtually, will also allow participants to schedule one-on-one meetings with Glover. With over 37 million Americans suffering from chronic kidney disease, ZyVersa is advancing its pipeline to address this significant unmet medical need.

ZyVersa Therapeutics (Nasdaq: ZVSA) announced its Q1-2024 financial results and provided a business update. Net losses were $2.8 million, a 20.2% improvement from Q1-2023. The company has $2.0 million in cash, sufficient for month-to-month operations but will need additional financing. Key developments include the initiation of a Phase 2a clinical trial for Cholesterol Efflux MediatorTM VAR 200 in diabetic kidney disease and upcoming GLP toxicology studies for Inflammasome ASC Inhibitor IC 100. Other milestones include preclinical data readouts and collaborations for IC 100, focusing on atherosclerosis and obesity-related conditions. ZyVersa raised $2.7 million through warrant exercises.

ZyVersa Therapeutics announced that CEO Stephen C. Glover will participate in the 2024 BIO International Convention in San Diego from June 3-6, 2024. ZyVersa is developing treatments for renal and inflammatory diseases using two proprietary technologies: the Cholesterol Efflux Mediator™ VAR 200 and the Inflammasome ASC Inhibitor IC 100. The company plans to start a Phase 2a clinical trial for VAR 200 in diabetic kidney disease in the first half of 2024 and is conducting preclinical studies for expanding IC 100's indications to atherosclerosis, obesity, and Parkinson’s disease. An IND filing for IC 100 is expected by year-end, with Phase 1 trials starting in Q1-2025. Glover will be available for one-on-one meetings to discuss these developments.

ZyVersa Therapeutics, Inc. announces a publication highlighting the role of inflammasome-mediated inflammation in Alzheimer's Disease (AD) and its impact on heart health. The company is developing Inflammasome ASC Inhibitor IC 100 to target multiple inflammasomes and reduce inflammation. The research indicates a potential therapeutic target for cardiac comorbidities in AD and beyond.